Skip to main content
Premium Trial:

Request an Annual Quote

GeneLink Raises $2.4M in Private Placements

NEW YORK (GenomeWeb News) – GeneLink today said that it has raised $2.4 million through two private placements of its stock.

The consumer genomics firm said that it closed the first placement in January and the second one on Feb. 27. According to the firm's CEO, Monte Taylor, funding came from shareholders of GeneLink, which is publicly traded on the OTC Bulletin Board, marketing affiliates of GeneWize Life Sciences, and "arms-length" financial investors.

GeneWize is a wholly owned subsidiary of Orlando, Fla.-based GeneLink and is focused on marketing nutritional supplements and skincare products specifically tailored to an individual's genetic makeup.

Taylor said in a statement that the funds from the private placements would be used to "upgrade the infrastructure of GeneWize to enable us to support the anticipated demand for our products and services."

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.